E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Intracerebral haemorrhage |
|
E.1.1.1 | Medical condition in easily understood language |
Bleeding into the brain (stroke) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019016 |
E.1.2 | Term | Haemorrhagic stroke |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the feasibility of randomising, administering the intervention, and completing follow-up for patients treated with desmopressin or placebo to inform a definitive trial.
|
|
E.2.2 | Secondary objectives of the trial |
To assess the effect of desmopressin on secondary outcomes: clinical outcomes, safety outcomes, laboratory outcomes, costs and radiological efficacy.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Adults (>16 years) Confirmed intracerebral haemorrhage on imaging Less than 12 hours from onset of symptoms [or from when last seen healthy] Prescribed and thought to be taking a daily oral antiplatelet drug in the preceding seven days (cyclooxygenase inhibitors, phosphodiesterase inhibitors or P2Y12 inhibitors) Signed consent (patient/personal/professional representative)
|
|
E.4 | Principal exclusion criteria |
Aneurysmal subarachnoid haemorrhage known at time of enrolment Haemorrhage known to be due to transformation of infarction Haemorrhage known to be due to thrombolytic drug Haemorrhage known to be due to venous thrombosis Risk/s of fluid retention associated with desmopressin judged clinically significant by the attending physician (for example patients with pulmonary oedema and/or cardiac failure) Significant hypotension (systolic blood pressure <90mmHg) Known drug-eluting coronary artery stent in previous three months Allergy to desmopressin Pregnant or breast-feeding Life expectancy less than four hours, or planned for palliative care only Glasgow coma scale less than 5 mRS >4 Participation in another concurrent drug trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess the feasibility of randomising, administering the intervention, and completing follow-up for patients treated with desmopressin or placebo to inform a definitive trial. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Hyponatraemia at 24 hours; early case fatality <28 days; case fatality at day 90; serious adverse events (including thromboembolic events) up to day 90; change in intracerebral haemorrhage volume at 24 hours; discharge destination; disability (Barthel index, day 90); quality of life (EuroQol, day 90); cognition (telephone MMSE day 90); length of hospital stay; health economic assessment (EQ-5D); assessment of baseline platelet dysfunction (P-selectin) and correlation with response to desmopressin; change in factor VIII, VWF antigen and VWF activity, one hour after administration of desmopressin. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
I hour: assessment of baseline platelet dysfunction (P-selectin) and correlation with response to desmopressin; change in factor VIII, VWF antigen and VWF activity 24 hours: Hyponatraemia, Change in intracerebral haemorrhage volume 28 days: Early mortality Day 90 (up to and including): Mortality Serious adverse events (including thromboembolic events) Compliance with intervention Disability (Barthel index), Quality of life (EuroQol), Health economic assessment (EQ-5D), Cognition (telephone MMSE) Proportion of eligible patients randomised and reasons for non-randomisation Proportion of participants followed up to 90 days and reasons for loss to follow up Proportion of randomised participants with full outcome data available, and reasons for non-availability
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 30 |